Rigel Pharmaceuticals (RIGL) Common Equity (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Common Equity of $399.9 million for Q1 2026, up 2053.81% year-over-year from $18.6 million in Q1 2025, and up 2.15% quarter-over-quarter from $391.5 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Common Equity (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $399.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 2053.81% year-over-year to $399.9 million; the TTM figure through Mar 2026 stood at $399.9 million (up 2053.81% YoY), while the FY2025 annual figure was $391.5 million, up 11806.33% from the prior year.
- Common Equity for Q1 2026 stood at $399.9 million, up from $391.5 million in the prior quarter.
- The five-year high for Common Equity was $399.9 million in Q1 2026, with the low at -$31.8 million in Q3 2023.
- The 5-year median for Common Equity is -$13.6 million (2022), against an average of $46.7 million.
- The sharpest annual moves came in 2023 and 2025: Common Equity plunged 664.62% in 2023, then jumped 11806.33% in 2025.
- Rigel Pharmaceuticals' Common Equity stood at -$13.6 million in 2022, then slumped by 110.37% to -$28.6 million in 2023, then jumped by 111.48% to $3.3 million in 2024, then surged by 11806.33% to $391.5 million in 2025, then rose by 2.15% to $399.9 million in 2026.
- Business Quant data shows RIGL's Common Equity at $399.9 million in Q1 2026, $391.5 million in Q4 2025, and $117.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 425.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 425.42 Mn |
| Mar 31, 2026 | 399.90 Mn |
| Dec 31, 2025 | 391.48 Mn |
| Sep 30, 2025 | 117.61 Mn |
| Jun 30, 2025 | 81.93 Mn |
| Mar 31, 2025 | 18.57 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | -14.64 Mn |
| Jun 30, 2024 | -29.91 Mn |
| Mar 31, 2024 | -31.67 Mn |
| Dec 31, 2023 | -28.64 Mn |
| Sep 30, 2023 | -31.83 Mn |
| Jun 30, 2023 | -28.12 Mn |
| Mar 31, 2023 | -24.26 Mn |
| Dec 31, 2022 | -13.62 Mn |
| Sep 30, 2022 | -19.83 Mn |
| Jun 30, 2022 | -3.68 Mn |
| Mar 31, 2022 | 6.80 Mn |
| Dec 31, 2021 | 30.37 Mn |
| Sep 30, 2021 | 49.67 Mn |